Pular para o conteúdo
Merck
Todas as fotos(1)

Key Documents

View All Documentation

1478800

USP

Orlistat

United States Pharmacopeia (USP) Reference Standard

Sinônimo(s):

(−)-Tetrahydrolipstatin, N-Formyl-L-leucine (1S)-1-[[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl]dodecyl ester, Ro-18-0647

Faça loginpara ver os preços organizacionais e de contrato
Todas as fotos(1)

About This Item

Fórmula empírica (Notação de Hill):
C29H53NO5
Número CAS:
96829-58-2
Peso molecular:
495.73
Número MDL:
MFCD05662360
Código UNSPSC:
41116107
ID de substância PubChem:
329750618
NACRES:
NA.24

grau

pharmaceutical primary standard

família API

orlistat

fabricante/nome comercial

USP

aplicação(ões)

pharmaceutical (small molecule)

formato

neat

cadeia de caracteres SMILES

CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O

InChI

1S/C29H53NO5/c1-5-7-9-11-12-13-14-15-16-18-24(34-29(33)26(30-22-31)20-23(3)4)21-27-25(28(32)35-27)19-17-10-8-6-2/h22-27H,5-21H2,1-4H3,(H,30,31)/t24-,25-,26-,27-/m0/s1

chave InChI

AHLBNYSZXLDEJQ-FWEHEUNISA-N

Informações sobre genes

human ... LIPF(8513) , PNLIP(5406)

Procurando produtos similares? Visita Guia de comparação de produtos

Descrição geral

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicação

Orlistat USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.

Ações bioquímicas/fisiológicas

Orlistat, used in obesity research, is a pancreatic lipase inhibitor that acts locally in the gastrointestinal tract to inhibit lipase.

Nota de análise

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Outras notas

Solution is not completely clear, small particles may remain floating.
Sales restrictions may apply.

produto relacionado

Nº do produto
Descrição
Preços

1478833

Orlistat Related Compound C, United States Pharmacopeia (USP) Reference Standard

1478811

Orlistat Related Compound A, United States Pharmacopeia (USP) Reference Standard

1478844

Composto D relacionado ao orlistato, United States Pharmacopeia (USP) Reference Standard

1478855

Orlistat Related Compound E, United States Pharmacopeia (USP) Reference Standard

1478822

Orlistat Related Compound B, United States Pharmacopeia (USP) Reference Standard

1680685

Tributyl phosphine oxide, United States Pharmacopeia (USP) Reference Standard

PHR2544

Orlistat Related Compound C, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2543

Orlistat Related Compound B, Pharmaceutical Secondary Standard; Certified Reference Material

Código de classe de armazenamento

11 - Combustible Solids

Classe de risco de água (WGK)

WGK 3

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable

Certificados de análise (COA)

Busque Certificados de análise (COA) digitando o Número do Lote do produto. Os números de lote e remessa podem ser encontrados no rótulo de um produto após a palavra “Lot” ou “Batch”.

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Juliet M Mancino
Current diabetes reports, 6(5), 389-394 (2006-11-02)
Orlistat, a pancreatic lipase inhibitor, was approved by the US Food and Drug Administration (FDA) in the spring of 1999 as an adjunct to lifestyle intervention for weight loss. This paper seeks to examine current issues regarding orlistat use in
Robert H Nelson et al.
Expert opinion on pharmacotherapy, 6(14), 2483-2491 (2005-11-02)
Orlistat (tetrahydrolipstatin) is an inhibitor of gastrointestinal lipases, especially pancreatic lipase. It is used as an adjunct to diet and exercise in order to achieve weight loss in obese individuals (body mass index > 30 kg/m2) or in overweight individuals
D N Kiortsis et al.
Diabetes & metabolism, 31(1), 15-22 (2005-04-02)
Orlistat is an antiobesity drug with a well documented efficacy in weight reduction and weight maintenance. Weight reduction with orlistat has been associated with a favourable effect on obesity-related cardiovascular risk factors. Orlistat treatment is associated with a reduction in
György Paragh et al.
Orvosi hetilap, 146(11), 493-498 (2005-04-09)
The overweight and obesity represent severe problems for the health management system of developed countries. In the evolution of obesity, beside genetic background, the environmental factors also play important roles. In the daily routine, the majority of obese patients need
Sheridan Henness et al.
Drugs, 66(12), 1625-1656 (2006-09-08)
Orlistat (Xenical) is a reversible inhibitor of gastric and pancreatic lipases. In conjunction with a hypocaloric diet and moderate exercise, orlistat is an effective drug for use in the management of obesity in adults with or without comorbidities. Recent data
Exibir todos os documentos relacionados

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica